Targets › SMO
8 programs from 8 companies in 11 trials: 8 Phase 2, 3 Phase 1; Oncology, Respiratory; next expected readout Dec 2026.
G protein-coupled receptor, which transduces the smoothened signaling pathway. Activated by cholesterol in response to hedgehog (DHH, IHH or SHH) morphogens. (UniProt, Q99835)
Open in Phaseline: the race on SMO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gruppo Oncologico del Nord-Ovest | Sonidegib Smoothened homolog inhibitor | SMO | Phase 2 | Locally Advanced Basal Cell Carcinoma | Dec 2026 |
| National Cancer Institute (NCI) | Vismodegib (GDC-0449) Smoothened homolog inhibitor | SMO | Phase 2 | Advanced Lymphoma; Clear Cell Chondrosarcoma; Adult Solid Neoplasm | Dec 2026 |
| University of Florida | Sonidegib Smoothened homolog inhibitor | SMO | Phase 2 | Hepatocellular Carcinoma | Apr 2027 |
| University of California, Irvine | Glasdegib Smoothened homolog antagonist | SMO | Phase 2 | Acute Myelogenous Leukemia (AML) Due to Therapy | Jun 2027 |
| VA Office of Research and Development | Itraconazole Cytochrome P450 51 inhibitor | SMO, AKT1, VEGFA | Phase 2 | Esophageal Adenocarcinoma | Apr 2029 |
| University Hospital, Lille | Sonidegib Smoothened homolog inhibitor | SMO | Phase 2 | Basal Cell Carcinoma | Jun 2029 |
| Endeavor Biomedicines | Taladegib (ENV-101) Smoothened homolog antagonist | SMO | Phase 2 | Idiopathic Pulmonary Fibrosis | – |
| Nathalie Zeitouni | Sonidegib Smoothened homolog inhibitor | SMO | Phase 1 | Basal Cell Carcinoma (BCC) | Dec 2026 |
Idiopathic Pulmonary Fibrosis (2) Locally Advanced Basal Cell Carcinoma (1) Basal Cell Carcinoma (BCC) (1) Acute Myelogenous Leukemia (AML) Due to Therapy (1) Advanced Lymphoma (1) Clear Cell Chondrosarcoma (1) Adult Solid Neoplasm (1) Basal Cell Carcinoma (1) Hepatocellular Carcinoma (1) Esophageal Adenocarcinoma (1)
small molecule (8)
Gruppo Oncologico del Nord-Ovest (1) Nathalie Zeitouni (1) University of California, Irvine (1) Endeavor Biomedicines (1) National Cancer Institute (NCI) (1) University Hospital, Lille (1) University of Florida (1) VA Office of Research and Development (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.